Caplin Point Laboratories Ltd Q1 FY27 Earnings Analysis

Published 14 Jun 2026 | Market Cap: ₹13.0K Cr

Price

2,408

Market Cap

₹13.0K Cr

P/E Ratio

21.2

Earnings Summary

No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.

📊 Revenue & Sales Performance

No information is provided regarding the same in the latest conference call.

📈 Profitability & Margins

No information is provided regarding the same in the latest conference call.

🏗️ Capital Expenditure Plans

No information is provided regarding the same in the latest conference call.

💰 Fundraising & Capital Structure

No information is provided regarding the same in the latest conference call.

📋 Order Book & Pipeline

No information is provided regarding the same in the latest conference call.

Key Metrics

Frequently Asked Questions

What were Caplin Point Laboratories Ltd Q1 FY27 results?

No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.

What is Caplin Point Laboratories Ltd share price analysis?

Caplin Point Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 21.2 with a market cap of ₹12,990. Investors should review the full earnings analysis for detailed insights.

Is Caplin Point Laboratories Ltd planning capital expenditure?

No information is provided regarding the same in the latest conference call.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

Others in Pharmaceuticals & Biotechnology this season

  • Sat Kartar Life Ltd (Q1 FY27)

    Sat Kartar Life Ltd Q1 FY27 quarterly results analysis. - FY 27 product revenue target: ₹300 crores, driven by: - Current run rate at ₹225 crores with expecte

  • OneSource Specialty Pharma Ltd (Q1 FY27)

    OneSource Specialty Pharma Ltd Q1 FY27 quarterly results analysis. - OneSource expects strong growth in FY27 and FY28, with meaningful revenue contributions sta

  • Bharat Parenterals Ltd (Q1 FY27)

    Bharat Parenterals Ltd Q1 FY27 quarterly results analysis. - Standalone business: - Expected revenue growth of 10% to 15% in FY '27, based on INR 230 crores b

  • Sanjivani Paranteral Ltd (Q1 FY27)

    Sanjivani Paranteral Ltd Q1 FY27 quarterly results analysis. - FY'27 total revenue guidance: INR 80-85 crores from base business; INR 60-65 crores from Pune IV